-
EP3229800
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3229800
| EP3229800 - USE OF PAN FGFR INHIBITORS AND METHOD OF IDENTIFYING PATIENTS WITH CANCER ELIGIBLE FOR TREATMENT WITH A PAN FGFR INHIBITOR [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 22.01.2021 Database last updated on 02.09.2024 | |
| Former | Examination is in progress Status updated on 15.03.2019 | ||
| Former | Request for examination was made Status updated on 15.09.2017 | ||
| Former | The international publication has been made Status updated on 26.05.2017 | Most recent event Tooltip | 22.01.2021 | Change: Date of cancellation oral proceedings | 22.01.2021 | New entry: Date of cancellation oral proceedings | 22.01.2021 | Withdrawal of application | published on 24.02.2021 [2021/08] | Applicant(s) | For all designated states Bayer Pharma Aktiengesellschaft Müller Strasse 178 13353 Berlin / DE | [2017/42] | Inventor(s) | 01 /
ELLINGHAUS, Peter Auf der Obstwiese 3 49324 Melle / DE | 02 /
HEROULT, Melanie Ulenberg Str. 3d 40223 Düsseldorf / DE | [2017/42] | Representative(s) | BIP Patents c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50 40789 Monheim am Rhein / DE | [N/P] |
| Former [2017/42] | BIP Patents c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 10 40789 Monheim am Rhein / DE | Application number, filing date | 15805493.2 | 08.12.2015 | [2017/42] | WO2015EP78919 | Priority number, date | EP20140197400 | 11.12.2014 Original published format: EP 14197400 | [2017/42] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2016091849 | Date: | 16.06.2016 | Language: | EN | [2016/24] | Type: | A2 Application without search report | No.: | EP3229800 | Date: | 18.10.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.06.2016 takes the place of the publication of the European patent application. | [2017/42] | Search report(s) | International search report - published on: | EP | 28.07.2016 | (Supplementary) European search report - dispatched on: | EP | 19.03.2019 | Classification | IPC: | A61K31/4184, A61K31/4965, A61K31/498, A61K31/506, A61K31/53, A61P35/00 | [2017/42] | CPC: |
A61K31/53 (EP,CN,IL,KR,US);
A61K45/00 (CN,IL);
A61K31/4184 (EP,CN,IL,KR,US);
A61K31/496 (EP,CN,IL,US);
A61K31/4965 (EP,IL,KR,US);
A61K31/498 (EP,CN,IL,KR,US);
A61K31/506 (EP,CN,IL,KR,US);
A61P35/00 (EP,IL,US);
C12Q1/6886 (IL,US);
C12Q2600/106 (IL,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/42] | Extension states | BA | 11.07.2017 | ME | 11.07.2017 | Title | German: | VERWENDUNG VON PAN-FGFR-INHIBITOREN UND VERFAHREN ZUR IDENTIFIZIERUNG VON PATIENTEN MIT KREBS, DIE ZUR BEHANDLUNG MIT EINEM PAN-FGFR-INHIBITOREN IN FRAGE KOMMEN | [2017/42] | English: | USE OF PAN FGFR INHIBITORS AND METHOD OF IDENTIFYING PATIENTS WITH CANCER ELIGIBLE FOR TREATMENT WITH A PAN FGFR INHIBITOR | [2017/42] | French: | UTILISATION D'INHIBITEURS CIBLANT TOUS LES FGFR ET PROCÉDÉ D'IDENTIFICATION DE PATIENTS SOUFFRANT D'UN CANCER ÉLIGIBLES POUR UN TRAITEMENT AVEC UN INHIBITEUR CIBLANT TOUS LES FGFR | [2017/42] | Entry into regional phase | 11.07.2017 | National basic fee paid | 11.07.2017 | Designation fee(s) paid | 11.07.2017 | Examination fee paid | Examination procedure | 30.06.2017 | Date on which the examining division has become responsible | 11.07.2017 | Examination requested [2017/42] | 22.01.2018 | Amendment by applicant (claims and/or description) | 19.03.2019 | Despatch of a communication from the examining division to which search results under Rule 164(2) EPC are annexed (Time limit: M06) [2019/16] | 19.03.2019 | Despatch of a communication from the examining division (Time limit: M06) | 27.09.2019 | Reply to a communication from the examining division | 19.01.2021 | Application withdrawn by applicant [2021/08] | 19.01.2021 | Cancellation of oral proceeding that was planned for 15.03.2021 | 15.03.2021 | Date of oral proceedings (cancelled) | Fees paid | Renewal fee | 12.12.2017 | Renewal fee patent year 03 | 12.12.2018 | Renewal fee patent year 04 | 13.12.2019 | Renewal fee patent year 05 | 14.12.2020 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2011128701 (IMP INNOVATIONS LTD [GB], et al) [X] 1,30,31 * claims 1, 20 * [I] 2-5,17-19,25-29; | [AD]US2013158000 (BROHM DIRK [DE], et al) [AD] 1-5,17-19,25-31* claim - *; | [XI] - H ZHANG ET AL, "Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models", BRITISH JOURNAL OF CANCER, GB, (20140121), vol. 110, no. 2, doi:10.1038/bjc.2013.754, ISSN 0007-0920, pages 320 - 329, XP055246574 [X] 1,2,18,30,31 * page 327 * [I] 3-5,17,19,25-29 DOI: http://dx.doi.org/10.1038/bjc.2013.754 | [A] - "Suppl. data to Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models", (20140121), URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899776/bin/bjc2013754x1.ppt, (20160203), XP055247082 [A] 1-5,17-19,25-31 * figure S2 * | [XI] - NILS C LEHNEN ET AL, "Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma", HISTOPATHOLOGY., GB, (20130628), vol. 63, no. 2, doi:10.1111/his.12115, ISSN 0309-0167, pages 157 - 166, XP055246591 [X] 1,2,17,18,26,30,31 * figure 4 * [I] 3-5,19,25,27-29 DOI: http://dx.doi.org/10.1111/his.12115 | [XDI] - M. W. WYNES ET AL, "FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies", CLINICAL CANCER RESEARCH, US, (20140615), vol. 20, no. 12, doi:10.1158/1078-0432.CCR-13-3060, ISSN 1078-0432, pages 3299 - 3309, XP055246497 [XD] 1,2,18,30,31 * page 3302, paragraph l - page 3303 * [I] 1,3-5,19,25-29 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-13-3060 | [XDI] - M. E. MARSHALL ET AL, "Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells", CLINICAL CANCER RESEARCH, (20110614), vol. 17, no. 15, doi:10.1158/1078-0432.CCR-11-0050, ISSN 1078-0432, pages 5016 - 5025, XP055180409 [XD] 1-5,18,19,30,31 * figure 1c * * page 5020, column 1 * [I] 17,25-29 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-11-0050 | [X] - R. GYANCHANDANI ET AL, "A Proangiogenic Signature Is Revealed in FGF-Mediated Bevacizumab-Resistant Head and Neck Squamous Cell Carcinoma", MOLECULAR CANCER RESEARCH, US, (20131003), vol. 11, no. 12, doi:10.1158/1541-7786.MCR-13-0358, ISSN 1541-7786, pages 1585 - 1596, XP055246944 [X] 1-5,18,19,30,31 * page 1592, column 1 * DOI: http://dx.doi.org/10.1158/1541-7786.MCR-13-0358 | [A] - P T NGUYEN ET AL, "The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1", BRITISH JOURNAL OF CANCER, GB, (20130917), vol. 109, no. 8, doi:10.1038/bjc.2013.550, ISSN 0007-0920, pages 2248 - 2258, XP055247675 [A] 1-5,17-19,25-31 * figure 5 * DOI: http://dx.doi.org/10.1038/bjc.2013.550 | Examination | EP2695950 | WO2016105503 | - JÖRG HÄNZE ET AL, "Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells", BMC CANCER, BIOMED CENTRAL, LONDON, GB, (20131211), vol. 13, no. 1, doi:10.1186/1471-2407-13-589, ISSN 1471-2407, page 589, XP021171013 DOI: http://dx.doi.org/10.1186/1471-2407-13-589 | - TIEWEI CHENG ET AL, "Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting", PLOS ONE, (20130226), vol. 8, no. 2, doi:10.1371/journal.pone.0057284, page e57284, XP055554959 DOI: http://dx.doi.org/10.1371/journal.pone.0057284 | - ELIZABETH A. GUANCIAL ET AL, "FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder", CANCER MEDICINE, GB, (20140521), vol. 3, no. 4, doi:10.1002/cam4.262, ISSN 2045-7634, pages 835 - 844, XP055554973 DOI: http://dx.doi.org/10.1002/cam4.262 | - MAZZOLA C R ET AL, "Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder", EXPERT OPINION ON INVESTIGATIONAL DRUGS, INFORMA HEALTHCARE, UK, vol. 23, no. 11, doi:10.1517/13543784.2014.966900, ISSN 1354-3784, (20141101), pages 1553 - 1562, (20141004), XP002756575 DOI: http://dx.doi.org/10.1517/13543784.2014.966900 | by applicant | - SWINNEY; ANTHONY, NATURE REV. DRUG DISC., (2011), vol. 10, no. 7, pages 507 - 519 | - POLANSKA ET AL., DEVELOPMENTAL DYNAMICS, (2009), vol. 238, no. 2, pages 277 - 293 | - KORC; FRIESEL, CURR. CANCER DRUGS TARGETS, (2009), vol. 5, pages 639 - 651 | - BERGERS; HANAHAN, NAT. REV. CANCER, (2008), vol. 8, pages 592 - 603 | - WESCHE ET AL., BIOCHEM. J., (2011), vol. 437, no. 2, pages 199 - 213 | - LIM ET AL., FUTURE ONCOL., (201303), vol. 9, no. 3, pages 377 - 386 | - BOEHM D. ET AL., VIRCHOWS ARCH., (201405), vol. 464, no. 5, pages 547 - 551 | - MAESSENHAUSEN ET AL., ANNALS OF TRANSLATIONAL MEDICINE, (201310), vol. 1, no. 3 | - LIAO, RG, CANCER RES., (20130815), vol. 73, no. 16, pages 5195 - 5205 | - MARSHALL ME ET AL., CLIN CANCER RES., (20110801), vol. 17, no. 15, pages 5016 - 5025 | - BANDLA ET AL., ANN THORAC SURG., (201204), vol. 93, no. 4, pages 1101 - 1106 | - KATO H ET AL., INT J ONCOL., (201304), vol. 42, no. 4, pages 1151 - 1158 | - DE-CHEN, L, NATURE GENETICS, (201405), vol. 46, no. 5 | - PATERSON ET AL., J PATHOL., (201305), vol. 230, no. 1, pages 118 - 128 | - THEILLET ET AL., GENES CHROMOSOM. CANCER, vol. 7, pages 219 - 226 | - TANIGUCHI ET AL., INT J GYNECOL CANCER, (201306), vol. 23, no. 5, pages 791 - 796 | - GUAGNANO ET AL., CANCER DISCOV, (201212), vol. 2, no. 12, pages 1118 - 1133 | - MARTIGNETTI ET AL., NEOPLASIA, (201401), vol. 16, no. 1, pages 97 - 103 | - FERNANDA-AMARY ET AL., CANCER MED., (201408), vol. 3, no. 4, pages 980 - 987 | - HEINZLE ET AL., EXPERT OPIN. THER. TARGETS, (2011), vol. 15, no. 7, pages 829 - 846 | - GREULICH; POLLOCK, TRENDS IN MOLECULAR MEDICINE, (2011), vol. 17, no. 5, pages 283 - 292 | - HAUGSTEN ET AL., MOL. CANCER RES., (2010), vol. 8, no. 11, pages 1439 - 1452 | - WYNES ET AL., CLIN CANCER RES., (20140615), vol. 20, no. 12, pages 3299 - 3309 | - S. M. BERGE ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560 DOI: http://dx.doi.org/10.1002/jps.2600660104 | - WANG ET AL., J MOL DIAGN., (201201), vol. 14, no. 1, pages 22 - 29 | - JIN; LLOYD, J CLIN LAB ANAL., (1997), vol. 11, no. 1, pages 2 - 9 | - LEVSKY; SINGER, J CELL SCI., (20030715), vol. 116, pages 2833 - 2838 | - LIVAK; SCHMITTGEN, METHODS, (200112), vol. 25, no. 4, pages 402 - 408 | - EUROPEAN JOURNAL OF CANCER, (2009), vol. 45, pages 228 - 247 |